GT Biopharma, Inc. — Q3 2021 Form 10-Q
Business context and reporting period. This clinical-stage biopharmaceutical company is developing TriKE immune-cell engager therapies, primarily for cancer, with research also directed toward HIV. The filing covers the quarter and nine months ended September 30, 2021. The company had no approved products and generated no revenue.
Financial performance and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $1.008 million | $(0.084) million | $3.287 million | $0.252 million |
| Selling, general and administrative | $4.946 million | $2.029 million | $36.050 million | $4.321 million |
| Operating loss | $5.954 million | $1.945 million | $39.337 million | $4.573 million |
| Net loss | $5.453 million | $2.876 million | $39.991 million | $22.006 million |
| Basic and diluted loss per share | $0.17 | $0.64 | $1.54 | $5.13 |
- Cash and liquidity: At September 30, cash and cash equivalents were $9.682 million and short-term investments were $26.031 million, totaling $35.713 million at fair value. Current assets were $35.798 million; current liabilities were $3.922 million.
- Cash flow, nine months: Operating activities used $11.901 million; investing activities used $26.031 million, primarily for investment purchases; financing activities provided $42.317 million. Ending cash was $9.682 million.
- Debt: Convertible notes and $5.527 million of accrued interest were mandatorily converted in February 2021 into 11.413 million common shares. No convertible notes remained at quarter-end; the line of credit balance was $31,000.
- Equity: Stockholders’ equity was $31.876 million, versus a $29.433 million deficit at December 31, 2020. Common shares outstanding were 30.508 million at quarter-end; 1.004 million additional conversion shares were still issuable. The company reported 30,582,354 shares outstanding as of November 12, 2021.
Profit margins are not meaningful because the company reported no revenue and incurred operating losses.
Material changes versus prior periods
- Nine-month operating loss increased to $39.337 million from $4.573 million. SG&A rose by $31.729 million, largely reflecting stock-based compensation, including $24.553 million for the nine-month period, alongside added personnel, public-company costs, professional fees and insurance.
- Nine-month R&D increased by $3.035 million, attributed primarily to clinical-trial activity and stock issued for research and development. Management expected R&D costs to rise further during the remainder of 2021 as development continued.
- Nine-month net loss included substantial noncash and unusual items. In 2021, stock-based compensation was significant; in 2020, results included $11.206 million of settlement expense and $6.227 million of interest expense. Interest expense fell to $0.696 million in 2021 after debt conversion.
- The February public offering generated $24.679 million net proceeds; warrant exercises generated $16.433 million. The offering and Nasdaq listing also triggered mandatory debt conversion. Common shares outstanding increased materially during the period.
Outlook, risks and contingencies
- Going concern: Management stated that recurring losses and operating cash use raise substantial doubt about the company’s ability to continue as a going concern. It said additional financing is needed and may include equity or debt offerings, strategic research and development funding, or licensing and marketing arrangements. The filing gives differing runway estimates: the notes say funds on hand were expected to support operations for six months, while MD&A says planned financing efforts, if successful, could support at least nine months from issuance. Neither estimate is assured.
- Management anticipated SG&A cash use of $2–3 million in coming quarters, with R&D spending varying with clinical activity. The company expected losses to continue and had no product-sales revenue.
- A lawsuit brought by former collaborators alleges breaches of license and consulting agreements; the filing describes damages and stock-related claims, and reports a May 2022 trial date. The company disputes the claims. A separate lease dispute was settled for $100,000 in July 2021.
- The University of Minnesota license carries royalties of 5%–6%, milestone payments totaling $3.1 million and future minimum annual royalties after first commercial sale. The company recorded $550,000 of R&D expense under the agreement during the period.
- Disclosure controls were reported ineffective due to material weaknesses involving segregation of duties, risk of executive override, and insufficient written accounting and reporting procedures. Management described remediation plans.
- After quarter-end, the company terminated its CEO and CFO in November 2021 and appointed an interim CEO, acting CFO and executive chairman. The filing disclosed compensation terms for the new leadership appointments.
- The company said COVID-19 affected operating results, but it could not predict the duration or magnitude of effects. It reported no identified asset impairment or significant COVID-related change in asset fair values.
Key facts for investors to verify
- Whether the company obtained additional funding after the filing and its resulting cash runway; reconcile the six-month and nine-month runway statements.
- Clinical-trial progress, costs, and development plans for OXS-3650 and other TriKE candidates, including any subsequent regulatory or collaboration updates.
- The actual cash burn and the extent to which reported losses reflect noncash stock compensation and other unusual items.
- Final issuance and ownership impact of the remaining conversion shares, outstanding warrants, and other potential dilution.
- Developments in the collaborator litigation and the company’s remediation of its material weaknesses in financial reporting controls.